-+ 0.00%
-+ 0.00%
-+ 0.00%
Alpha Cognition Announces Publication Of US Patent Application Covering Benzgalantamine For Treating Persistent Post-Concussion Symptoms
Share
Listen to the news

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent No. 20260325541-A1, titled "Benzgalantamine for Treating Persistent Post-Concussion Symptoms."

The published application includes pending claims directed to methods of treating persistent post-concussion symptoms with benzgalantamine. The application describes the use of benzgalantamine in patients experiencing persistent symptoms following mild traumatic brain injury, including cognitive impairment, and includes multiple routes of administration.

The publication expands Alpha Cognition’s intellectual property portfolio supporting the potential development of benzgalantamine for neurological conditions beyond Alzheimer’s disease. The application also includes preclinical data evaluating benzgalantamine in animal models of traumatic brain injury, including findings related to sensorimotor and cognitive recovery, neuronal preservation, neurogenesis, lesion volume, and pathological phosphorylated tau.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending